Notice of IMC Shareholder Presentation

About this update from Skinbiotherapeutics Plc

SkinBioTherapeutics plc ("SkinBioTherapeutics" or the "Group" or the "Company") Presentation on Superdrug Commercial Agreement via Investor Meet Company platform   27 June 2025 - SkinBioTherapeutics plc (AIM: SBTX ) , a life science group focused on skin health, will be providing a short presentation to shareholders on Thursday 3 July 2025 at 11am BST about the recently signed exclusive UK commercial agreement with Superdrug Stores plc, one of the UK's leading beauty and health retailers, related to its AxisBiotix™ food supplements to alleviate the symptoms of inflammatory skin conditions. The presentation will be open to all existing and potential SkinBioTherapeutics shareholders. Investors who already follow SkinBioTherapeutics on the Investor Meet Company (IMC) platform will be invited automatically. Investors can sign up to Investor Meet Company for free   Here . The Company intends to hold an IMC shareholder presentation at a later date for a pre-close trading update. -Ends-    For more information please contact: SkinBioTherapeutics plc Stuart J. Ashman, CEO Simon Hewitson, COO   +44 (0) 191 495 7325   Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Sam Butcher Patrick Weaver   +44 (0) 020 7496 3000   Vigo Consulting (financial press) Rozi Morris   +44 (0) 20 7390 0230 [email protected]   Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of inflammatory skin conditions, is sold directly and via Amazon, and will be sold via an exclusive UK commercial deal with Superdrug Stores plc later in 2025 . The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.  The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com .  

View stock analysis, news, and events for Skinbiotherapeutics Plc